ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2649

“Point of Care” Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NPSLE)

Debbie Rybak1, Nicole Jordan1, Noa Schwartz1, Tamar Rubinstein2, Bryan Freilich3, Irene Blanco4 and Chaim Putterman5, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 3Psychiatry, Albert Einstein College of Medicine, Bronx, NY, 4Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 5The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: central nervous system involvement, Cognitive dysfunction and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose

There is currently no standardized tool to assess for NPSLE, and comprehensive neuropsychological testing can be lengthy and expensive. The Automated Neuropsychological Assessment Metric (ANAM) is a computerized battery of tests which has been successfully used to test cognitive function in SLE. The Cognitive Stability Index (CSI) is a web-based tool for assessing neurocognitive function which measures similar domains to the ANAM; however, it has not been studied in patients with SLE. Furthermore, in contrast to ANAM, CSI summary scores are not solely based on response speed, and thus may have a significant advantage over ANAM. Additionally, CSI can auto-invalidate subtests performed with insufficient patient effort. We aimed to evaluate and compare the utility of ANAM and CSI to assess NPSLE in the outpatient setting.

Methods

Subjects enrolled in the Einstein Lupus Cohort were eligible to participate. Subjects completed an NPSLE screening questionnaire (Mosca et al, 2011), with the presence of NPSLE defined by a screening score of >17 (NPSLE (+)). Subjects completed the ANAM and CSI tests (each taking ~30 minutes to complete). Eight cognitive domains were assessed by the ANAM and four by the CSI. The ANAM composite score measures average performance on all domains and is reported as a z score; four individual CSI factor scores for each cognitive domain are reported as standard scores (mean 100±15). Mann Whitney U tests assessed differences between NPSLE (+) and NPSLE (-) subjects. Pearson correlations were obtained for ANAM and CSI scores. 

Results

31 subjects completed the CSI, of which 20 also completed the ANAM. Of the 31 subjects, median age was 39 years, 94% were female, 42% were Hispanic and 63% were black. 74% were treated with corticosteroids (median prednisone dose 10 mg).

The median composite ANAM z-score, adjusted for sex/age, was -1.39 [-2.59, -0.98]. Median age-adjusted CSI standard factor scores ranged from 84-98 across the four cognitive domains. The median composite ANAM score was significantly different in the NPSLE(+)  patients compared to those who were NPSLE(-) (p=0.03). Of the eight domains evaluated by ANAM, learning, attention and spatial working memory differed significantly by screening score. Of the four CSI domains, response speed and memory differed significantly between the NPSLE(+) and NPSLE(-) subjects (p=0.03 and 0.01, respectively). The composite ANAM score and CSI factor scores correlated significantly with each other. Finally, anti-dsDNA antibodies, C3, C4, SLEDAI scores, and medications were not significantly associated with NPSLE.

Conclusion

Median cognitive test scores on both ANAM and CSI fell below the standard mean for normals, independent of NPSLE status. CSI factor memory scores were significantly lower in NPSLE(+) subjects, independent of their response speed. Since this cannot be inferred from the ANAM composite score, CSI may provide a more specific assessment of cognitive functioning. Overall, NPSLE was associated with significantly lower scores on both ANAM and CSI, suggesting that these are valuable “point of care” tools that can be easily implemented in the clinical setting for the diagnosis of NPSLE.


Disclosure:

D. Rybak,
None;

N. Jordan,
None;

N. Schwartz,
None;

T. Rubinstein,
None;

B. Freilich,
None;

I. Blanco,
None;

C. Putterman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/point-of-care-neurocognitive-testing-for-neuropsychiatric-systemic-lupus-erythematosis-npsle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology